PubMed | National Institute of Pharmaceutical Education and Research, P.A. College, CSIR - Central Electrochemical Research Institute, Shree Dhootapapeshwar Ayurvedic Research Foundation SDARF and National Health Research Institute
Type: Journal Article | Journal: Advanced pharmaceutical bulletin | Year: 2014
Metabolic disorders are a group of disorders, due to the disruption of the normal metabolic process at a cellular level. Diabetes Mellitus and Tyrosinaemia are the majorly reported metabolic disorders. Among them, Diabetes Mellitus is a one of the leading metabolic syndrome, affecting 5 to 7 % of the population worldwide and mainly characterised by elevated levels of glucose and is associated with two types of physiological event disturbances such as impaired insulin secretion and insulin resistance. Up to now, various treatment strategies are like insulin, alphaglucosidase inhibitors, biguanides, incretins were being followed. Concurrently, various novel therapeutic strategies are required to advance the therapy of Diabetes mellitus. For the last few decades, there has been an extensive research in understanding the metabolic pathways involved in Diabetes Mellitus at the cellular level and having the profound knowledge on cell-growth, cell-cycle, and apoptosis at a molecular level provides new targets for the treatment of Diabetes Mellitus. Receptor signalling has been involved in these mechanisms, to translate the information coming from outside. To understand the various receptors involved in these pathways, we must have a sound knowledge on receptors and ligands involved in it. This review mainly summarises the receptors and ligands which are involved the Diabetes Mellitus. Finally, researchers have to develop the alternative chemical moieties that retain their affinity to receptors and efficacy. Diabetes Mellitus being a metabolic disorder due to the glucose surfeit, demands the need for regular exercise along with dietary changes.
Nilakash S.,Shree Dhootapapeshwar Ayurvedic Research Foundation SDARF |
Jonnalagadda G.,Shree Dhootapapeshwar Ayurvedic Research Foundation SDARF |
Chawda M.B.,Shree Dhootapapeshwar Ayurvedic Research Foundation SDARF |
Thakur K.S.,Shree Dhootapapeshwar Ayurvedic Research Foundation SDARF |
And 2 more authors.
Pharmaceutical Sciences | Year: 2014
Background: Swamala (SWA)® is an Ayurvedic proprietary product used in the treatment of general debility and in immune-compromised conditions. Despite its usefulness, there is no published data on toxicity profile of SWA®. Objective: The main objective of the present study was to evaluate safety of SWA® in a 90 day repeated oral dose toxicity test in Wistar rats. Methods: SWA® at the doses of 0, 3, 6, and 15 g/kg was administered for 90 consecutive days. Body weights and feed consumption were recorded and analyzed. At termination of the study rats were sacrificed and observed for gross pathological changes. All organ parts were collected, weighed and preserved for histopathological examination and blood was collected from retro-orbital sinus for clinical biochemical analysis. Results: After 90 days of oral administration SWA® did not show any gross toxicological signs and histopathology also when compared with normal. All animals in Group IV showed significant increase in body weight as compared to that of control group animals. No mortality was observed throughout the period. Conclusion: Finally, it was concluded that SWA® having no toxicopathological effects at a dose of 15 g/Kg which is equivalent to five times the therapeutic dose administered orally for 90 days.